## How does Corowa-kun work?



Corowa-kun is the mascot of an online chatbot. This chatbot in LINE is used to answer COVID-19 vaccine frequently asked questions (FAQs) via text messages. As of May 10th, 70 FAQs are available.

**Results.** A total of 59,676 persons used Corowa-kun during February to April 2021. The most commonly accessed message categories were: "I have (select comorbidity), can I get a COVID-19 vaccine?" (23%); followed by questions on adverse reactions (22%) and how the vaccine works (20%). 10,192 users (17%) participated in the survey. Median age was 55 years (range 16 to 97), and most were female (74%). Intention to receive a COVID-19 vaccine increased from 59% to 80% after using Corowa-kun (p < 0.01). Overall, 20% remained hesitant: 16% (1,675) were unsure, and 4% (364) did not intend to be vaccinated. Factors associated with vaccine hesitancy were: age 16 to 34 (odds ratio [OR] = 3.7, 95% confidential interval [CI]: 3.0-4.6, compared to age  $\geq 65$ ), female sex (OR = 2.4, CI: 2.1-2.8), and history of another vaccine side-effect (OR = 2.5, CI: 2.2-2.9). Being a physician (OR = 0.2, CI: 0.1-0.4) and having received a flu vaccine the prior season (OR = 0.4, CI: 0.3-0.4) were protective.

COVID-19 vaccine acceptance increased and hesitancy decreased after using Corowa-kun, Japan, 2021 (n=10,192)



\*There was a statistically significant difference in responses between before and after using Corowa-kun (p < 0.01, Chi-square test).

Univariable logistic regression models of factors associated with COVID-19 vaccine hesitancy, Japan, 2021 (n=10,192)

	Vaccine hesitancy Vaccine acceptance N=2,039 N=8,153		Odds ratio		
Age					
16-34	229	11.2%	569	7.0%	3.7 (3.0-4.6)
35-49	648	31.8%	2046	25.1%	2.9 (2.5-3.5)
50-64	953	46.7%	3609	44.3%	2.4 (2.1-2.9)
≥65	209	10.3%	1929	23.7%	Ref
Sex					
Male	278	13.63%	2278	27.9%	Ref
Female	1727	84.7%	5816	71.3%	2.4 (2.1-2.8)
Other	3	0.2%	14	0.2%	NA
No answer	31	1.5%	45	0.6%	5.6 (3.5-9.1)
Educational attainment					
Elementary or junior high school	57	2.8%	151	1.9%	1.4 (1.0-1.9)
High school	660	32.4%	2008	24.6%	1.2 (1.1-1.3)
College or professional school	730	35.8%	2635	32.3%	Ref
Undergraduate school	536	26.3%	2966	36.4%	0.7 (0.6-0.7)
Postgraduate school	56	2.8%	393	4.8%	0.5 (0.4-0.7)
Employment status					
Full-time	724	35.5%	3142	38.5%	Ref
Part-time	631	31.0%	2097	25.7%	1.3 (1.2-1.5)
Student	27	1.3%	73	0.9%	1.6 (1.0-2.5)
Retied	59	2.9%	681	8.4%	0.4 (0.3-0.5)
Homemaker	437	21.4%	1555	19.1%	1.2 (1.1-1.4)
Unemployed due to COVID-19	37	1.8%	91	1.1%	1.8 (1.2-2.6)
Unemployed irrelevant to COVID-19	124	6.1%	514	6.3%	1.0 (0.8-1.3)
Healthcare worker					
Physician	7	0.3%	164	2.0%	0.2 (0.1-0.4)
Yes, but not physician	323	15.8%	1400	17.2%	0.9 (0.8-1.01)
No	1709	83.8%	6589	80.8%	Ref
Living with persons at age<16	452	22.2%	1506	18.5%	1.3 (1.1-1.4)
Living with persons at age≥65	647	31.8%	2994	36.7%	0.8 (0.7-0.9)
Have you had a flu shot within the past year?	1039	51%	5998	73.6%	0.4 (0.3-0.4)
Self-reported history of COVID-19					
Yes (I tested positive)	48	0.6%	10	0.5%	0.8 (0.4-1.7)
Yes (I had the symptoms but did not receive a	60	0.7%	23	1.1%	1.5 (0.9-2.5)
positive test)					
No	8045	80%	2006	98.4%	Ref
Have you had any vaccine side-effects?					
Yes	331	16.2%	644	7.9%	2.5 (2.2-2.9)
No	1424	69.8%	7051	86.5%	Ref
Unsure	284	13.9%	458	5.6%	3.1 (2.6-3.6)
Pregnancy status					
Pregnant	31	1.5%	36	0.4%	3.3 (2.0-5.3)
Not pregnant	1072	52.57 %	4087	50.1%	Ref
Desire to be pregnant	84	4.1%	144	1.8%	2.2 (1.7-2.9)
Not applicable	852	41.8%	3886	47.7%	0.8 (0.8-0.9)

Ref: reference NA: Logistic regression was not performed due to too small number  $(n{\leq}3)$ 

**Conclusion.** Corowa-kun reduced vaccine hesitancy by providing COVID-19 vaccine information in a messenger app. Mobile messenger apps could be leveraged to increase COVID-19 vaccine acceptance.

Disclosures. All Authors: No reported disclosures

## 440. Detection of COVID-19 Patients Requiring Escalation to ICU Status Using a Naïve Bayes Classifier

William R. Barnett, MS<sup>1</sup>; Chad Jaenke, BS<sup>1</sup>; Zachary Holtzapple, BS<sup>2</sup>; James Williams, MPH<sup>1</sup>; Nithin Kesireddy, MD<sup>1</sup>; Waleed Khokher, MD<sup>1</sup>; Ragheb Assaly, MD<sup>1</sup>; <sup>1</sup>The University of Toledo College of Medicine, Toledo, Ohio; <sup>2</sup>The University of Toledo College of Medicine, Toledo, Ohio

## Session: P-21. COVID-19 Research

**Background.** A naïve Bayes classifier is a popular tool used in assigning variables an equal and independent contribution to a binary decision. With respect to COVID-19 severity, the naïve Bayes classifier can consider different variables, such as age, gender, race/ethnicity, comorbidities, and initial laboratory values to determine the probability a patient may need to be admitted or transferred to an intensive care unit (ICU). The aim of this study was to develop a screening tool to detect COVID-19 patients that may require escalation to ICU status.

**Methods.** Patients hospitalized with COVID-19 were gathered from the end of March 2020 to the end of May 2020 from four hospitals in our metropolitan area. We began searching for potential variables to include in the classification model using chi-square analysis or calculating the optimal cutpoint to separate ICU and non-ICU status. After identifying significant variables, we began using standard procedures to construct a classifier. The dataset was split 7:3 to create samples for training and testing. To appraise the model's performance, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), area under the curve (AUC), and the Matthew's correlation coefficient (MCC) were calculated.

Table 1. Univariate analysis of variables in the COVID-19 dataset dichotomized by ICU status

Variable	Non-ICU (n = 397)	ICU (n=177)	P value
Age $\geq$ 55 years	260 (65.5)	150 (84.7)	< 0.001
Male	175 (44.1)	101 (57.1)	0.005
African American	143 (36.0)	63 (35.6)	0.997
Hypertension	276 (69.5)	132 (74.6)	0.257
Chronic kidney disease	67 (16.9)	60 (33.9)	< 0.001
Chronic obstructive pulmonary disease	58 (14.6)	40 (22.6)	0.026
Obstructive sleep apnea	49 (12.3)	42 (23.7)	0.001
Diabetes mellitus type II	136 (34.3)	91 (51.4)	< 0.001
Presenting with fever	252 (63.5)	122 (68.9)	0.242
Presenting with diarrhea	123 (31.0)	37 (20.9)	0.017
C-reactive protein $\geq 10~mg/L$	39 (9.8)	35 (19.8)	0.002
Lactate dehydrogenase $\geq 400 \; U/L$	145 (36.5)	95 (53.7)	< 0.001
$Ferritin \geq 550 \ ng/mL$	162 (40.8)	104 (58.8)	< 0.001
$Troponin-I \geq 0.1 \ ng/mL$	27 (6.8)	45 (25.4)	< 0.001

**Results.** A total of 574 COVID-19 patients were included in the study. There were 402 patients in the training sample and 172 patients in the testing sample. The naïve Bayes classifier demonstrated an overall accuracy result of 75.6% (95% CI; 68.5% – 81.8%) using the 14 variables listed in Table 1. The model was able to correctly classify 84.9% of ICU status patients (sensitivity), but only 54.7% of non-ICU status patients (specificity). The PPV and the NPV were 80.1% and 61.7%, respectively. The AUC was 0.717 (95% CI; 0.629 – 0.805) and the MCC was 0.410.

**Conclusion.** Our naïve Bayes classifier operates by recognizing certain aspects of severe COVID-19 cases and looking for the probability of the variables in said patients. We present a classification model that potentially could be used alongside other tools to screen patients with COVID-19 early in their hospital course to identify those needing escalation to ICU level care.

Disclosures. All Authors: No reported disclosures

441. The Effects of Race and Comorbidity Burden on Inflammatory Biomarkers Among Persons Hospitalized with COVID-19.

Yetunde A. Fatade, MD, MPH<sup>1</sup>; Lauren F. Collins, MD, MSc<sup>2</sup>;

Lauren F. Collins, MD, MSc<sup>2</sup>; Zakaria Almuwaqqat, MD<sup>1</sup>; ZhenChao Chen, MPH<sup>1</sup>; Mahadev Prasad, n/a<sup>1</sup>; Arshed Quyyumi, MD, FACC<sup>1</sup>; Igho Ofotokun, MD, MS<sup>1</sup>; <sup>1</sup>Emory University, Snellville, GA; <sup>2</sup>Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA